Trials / Completed
CompletedNCT02790944
Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer
Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer in Consecutive Cases Unselected for Family History
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (actual)
- Sponsor
- Ambry Genetics · Industry
- Sex
- All
- Age
- 18 Years – 89 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study will be to estimate the prevalence of germline mutations in patients who present consecutively within 12 weeks of a confirmed diagnosis of pancreatic ductal adenocarcinoma.
Detailed description
The proposed research is a multi-site prospective and observational plan to investigate the prevalence of germline mutations in patients diagnosed with pancreatic cancer. Thirty two genes will be analyzed, all of which have been associated with an increased risk for cancer. The genes are included on CancerNextTM a multi-gene next generation sequencing and array CGH test. The 32 genes include: APC, ATM, BARD1, BRCA1, BRCA2, BRIP1, BMPR1A, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, GREM1, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, POLD1, POLE, PTEN, RAD50, RAD51C, RAD51D, SMAD4, SMARCA4, STK11, and TP53 .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | Multi-gene Next Generation Sequencing Panel | Participants will have genetic testing |
Timeline
- Start date
- 2016-05-04
- Primary completion
- 2020-08-15
- Completion
- 2020-08-15
- First posted
- 2016-06-06
- Last updated
- 2020-08-25
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02790944. Inclusion in this directory is not an endorsement.